[ad_1]
Burjeel Holdings, in partnership with OncoHelix, has established a cutting-edge laboratory in Abu Dhabi to provide advanced molecular genetic, cellular and immunological testing to patients in the UAE.
Through this exclusive agreement, Burjeel and OncoHelix are working to bring personalized medicine to clinics and hospitals in the UAE.
The agreement was signed by Burjeel CEO John Sunil and OncoHelix CEO Dr Faisal Khan.
two fields
The new lab will be divided into two areas. An advanced diagnostic laboratories segment will focus on providing breakthrough molecular genetic and immunological analytical tests to assist oncologists and physicians in the diagnosis, risk stratification and tailored treat. The second unit will expand Burjeel’s existing translational research programs to analyze the genomic and immune signatures of cancer patients to develop innovative diagnostics and therapeutics.
Burjeel expects the new laboratory to be operational by the end of the year and it will be able to meet the needs of hospitals in the region.
Headquartered in Western Canada, OncoHelix has the largest clinically validated cancer comprehensive genomic profiling (CGP) panel in the country. As part of their academic role at the University of Calgary, OncoHelix scientists and clinicians have an impeccable record in translational research, with more than 350 publications in leading scientific journals.
Precision Oncology
Their translational research team develops impactful precision oncology and immunology pipelines aimed at improving clinical outcomes for cancer patients and transplant recipients.
Burjeel is one of the largest healthcare service providers in the MENA region, with a network of 61 properties, including 16 hospitals and 23 medical centers, as well as pharmacies and other related services. The group provides the highest standard of patient care in the region. Its laboratory services division, coLAB, operates a network of 12 internationally accredited laboratories, including 4 accredited by the College of American Pathologists.
“Burjeel Holdings continues to invest and form new partnerships to help facilitate the expansion of our translational research programs and improve patient outcomes,” said Sunil. The new venture will leverage OncoHelix’s clinical and academic experience to build a state-of-the-art Laboratory through which we will provide testing services that are not yet widely available in the UAE.
“Through this agreement, we hope to strengthen our position as the UAE’s leading provider of comprehensive care and enhance our ability to serve the country’s growing medical tourism market. As the UAE transforms into a global leader in healthcare, such The cooperation will benefit the UAE.”
Dr Khan said, “We are joining forces with Burjeel Holdings to create a local advanced diagnostic program that will not only facilitate the early and accurate diagnosis of malignancies and immune system disorders, but also pave the way for new treatment options guided by specific molecular Signature. The translational research program will investigate somatic and germline variation in cancer patients and immune signature patterns in transplant recipients and donors in the region to lead the development of precision medicine-based therapeutics.” — trade arab news agency
[ad_2]
Source link